Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Monday, September 28, 2026

What Instrument Protocol Did I Actually Use?

›
Puttering around with some ideas for future experiments on our autonomous lab, I realized a potential software engineering gap that in my ve...
Saturday, September 26, 2026

What About BOB-Seq?

›
An interesting new approach to short read RNA-Seq library preparation bobbed into view this week, using click chemistry to barcode samples b...
Sunday, September 20, 2026

Sequence That Moldy Lanternfly!

›
Googling on some keywords from a social media post led to an interesting PNAS article from 2019 on two fungi which can infect the spotted la...
Friday, September 18, 2026

Does Your Instrument Strand Its Data in an Proprietary Binary Format?

›
This week we hosted the first REAL (Readiness & Engagement For Automated Labs) Summit; today that was followed by Ginkgo Datapoints Summ...
1 comment:
Wednesday, September 16, 2026

A Marvelous Demonstration of This Proposition Which This Context Window is Too Narrow To Contain

›
My friend and former colleague Ash Jogalekar tweeted out an interesting result recently , which is now expanded into a preprint. Using an in...
1 comment:
Thursday, September 03, 2026

Notes On Instrument APIs Critiques I Delegated to Claude

›
In my previous post about the Model Hardware Standard from Anthropic , I mentioned some exploration I've been running on instrument API...
Monday, August 31, 2026

Model Hardware Standard: What Is It? Seriously, That's What I'm Asking.

›
Anthropic, the company behind Claude, announced a new initiative called the Model Hardware Standard (MHS).   It's a way to enable intell...
1 comment:
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.